AKBA
Price
$2.71
Change
-$0.00 (-0.00%)
Updated
Sep 26, 12:57 PM (EDT)
Capitalization
718.54M
41 days until earnings call
XERS
Price
$8.12
Change
+$0.26 (+3.31%)
Updated
Sep 26, 01:34 PM (EDT)
Capitalization
1.27B
41 days until earnings call
Interact to see
Advertisement

AKBA vs XERS

Header iconAKBA vs XERS Comparison
Open Charts AKBA vs XERSBanner chart's image
Akebia Therapeutics
Price$2.71
Change-$0.00 (-0.00%)
Volume$100
Capitalization718.54M
Xeris Biopharma Holdings
Price$8.12
Change+$0.26 (+3.31%)
Volume$755
Capitalization1.27B
AKBA vs XERS Comparison Chart in %
Loading...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKBA vs. XERS commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBA is a Hold and XERS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (AKBA: $2.71 vs. XERS: $7.85)
Brand notoriety: AKBA and XERS are both not notable
AKBA represents the Pharmaceuticals: Generic, while XERS is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKBA: 68% vs. XERS: 72%
Market capitalization -- AKBA: $718.54M vs. XERS: $1.27B
AKBA [@Pharmaceuticals: Generic] is valued at $718.54M. XERS’s [@Biotechnology] market capitalization is $1.27B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.86B. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKBA’s FA Score shows that 0 FA rating(s) are green whileXERS’s FA Score has 0 green FA rating(s).

  • AKBA’s FA Score: 0 green, 5 red.
  • XERS’s FA Score: 0 green, 5 red.
According to our system of comparison, XERS is a better buy in the long-term than AKBA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKBA’s TA Score shows that 3 TA indicator(s) are bullish while XERS’s TA Score has 4 bullish TA indicator(s).

  • AKBA’s TA Score: 3 bullish, 4 bearish.
  • XERS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, XERS is a better buy in the short-term than AKBA.

Price Growth

AKBA (@Pharmaceuticals: Generic) experienced а -8.45% price change this week, while XERS (@Biotechnology) price change was -5.42% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.65%. For the same industry, the average monthly price growth was +25.31%, and the average quarterly price growth was +68.49%.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.69%. For the same industry, the average monthly price growth was +9.02%, and the average quarterly price growth was +51.46%.

Reported Earning Dates

AKBA is expected to report earnings on Nov 06, 2025.

XERS is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.65% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

@Biotechnology (+3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XERS($1.27B) has a higher market cap than AKBA($719M). XERS YTD gains are higher at: 131.563 vs. AKBA (42.632). AKBA has higher annual earnings (EBITDA): 11M vs. XERS (7.39M). AKBA has more cash in the bank: 137M vs. XERS (59.3M). AKBA has less debt than XERS: AKBA (53.4M) vs XERS (257M). XERS has higher revenues than AKBA: XERS (246M) vs AKBA (204M).
AKBAXERSAKBA / XERS
Capitalization719M1.27B57%
EBITDA11M7.39M149%
Gain YTD42.632131.56332%
P/E RatioN/AN/A-
Revenue204M246M83%
Total Cash137M59.3M231%
Total Debt53.4M257M21%
FUNDAMENTALS RATINGS
AKBA vs XERS: Fundamental Ratings
AKBA
XERS
OUTLOOK RATING
1..100
5777
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
90
Overvalued
PROFIT vs RISK RATING
1..100
10062
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4737
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AKBA's Valuation (75) in the Biotechnology industry is in the same range as XERS (90) in the Pharmaceuticals Major industry. This means that AKBA’s stock grew similarly to XERS’s over the last 12 months.

XERS's Profit vs Risk Rating (62) in the Pharmaceuticals Major industry is somewhat better than the same rating for AKBA (100) in the Biotechnology industry. This means that XERS’s stock grew somewhat faster than AKBA’s over the last 12 months.

XERS's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as AKBA (100) in the Biotechnology industry. This means that XERS’s stock grew similarly to AKBA’s over the last 12 months.

XERS's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as AKBA (47) in the Biotechnology industry. This means that XERS’s stock grew similarly to AKBA’s over the last 12 months.

XERS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as AKBA (100) in the Biotechnology industry. This means that XERS’s stock grew similarly to AKBA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKBAXERS
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 29 days ago
86%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 12 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
79%
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JEPRX14.10N/A
N/A
JPMorgan Equity Premium Income R6
FADIX29.53N/A
N/A
Fidelity Advisor Diversified Intl M
FEVCX22.61N/A
N/A
First Eagle US C
SCATX65.68N/A
N/A
Virtus Zevenbergen Innovative Gr Stk I
KCRIX8.03N/A
N/A
Knights of Columbus Real Estt I

AKBA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with XERS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then XERS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
-2.17%
XERS - AKBA
39%
Loosely correlated
-1.88%
IPSC - AKBA
38%
Loosely correlated
+0.66%
SYRE - AKBA
37%
Loosely correlated
-8.18%
FENC - AKBA
36%
Loosely correlated
+3.57%
RXRX - AKBA
36%
Loosely correlated
-5.12%
More

XERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, XERS has been loosely correlated with MIRM. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if XERS jumps, then MIRM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XERS
1D Price
Change %
XERS100%
-1.88%
MIRM - XERS
50%
Loosely correlated
-0.93%
CRNX - XERS
43%
Loosely correlated
+2.02%
NUVL - XERS
40%
Loosely correlated
-2.54%
OCUL - XERS
39%
Loosely correlated
-2.55%
AKBA - XERS
39%
Loosely correlated
-2.17%
More